All HHS Contracts — October 21, 2026

PPD Development LP, a subsidiary of Pharmaceutical Product Development, LLC, holds a NIH/NIAID delivery order with $73,196,564 obligated and $51,830,763 outlayed to date (about 71%). The contract is cost-plus-fixed-fee under full and open competition with no set-aside.

The base-plus-options value of $186,449,775 is about 2.5x the current $73,196,564 obligation, implying roughly $113 million of option value if the government continues the program through the potential end date of 2031-01-31.

The record shows a 2024-01-24 award date and an October 21, 2026 reporting period, and the current end date of 2027-01-31 implies a roughly three-year performance window that conflicts with the stated period; the timing of spend and option decisions therefore cannot be verified from the data provided.

Parent company public status and the share of revenue attributable to this single delivery order are not disclosed, so the materiality of the award to any listed equity cannot be assessed.

Continued NIAID clinical site monitoring work could expand PPD Development LP's position in federal clinical research support if option periods are exercised and further funding increments are added.

The single record is a NIAID clinical site monitoring delivery order under NAICS 541714 and PSC AN12, indicating federal reliance on contracted clinical research oversight.

{"entity" => "PPD Development LP / Pharmaceutical Product Development, LLC", "reason" => "Substantial active spend ($51,830,763 outlayed against $73,196,564 obligated) and roughly $113M of unexercised option value on the NIAID clinical monitoring delivery order.", "trigger" => "Option exercise and funding modifications ahead of the 2027-01-31 current end date, and disclosure of parent public status"}